Adenosine Receptor
G protein-coupled receptors activated by adenosine. CBD inhibits adenosine reuptake, increasing extracellular adenosine levels and activating A1 and A2A receptors.
In Depth
Adenosine receptors mediate anti-inflammatory, cardioprotective, and neuroprotective effects. CBD's inhibition of adenosine reuptake may contribute to its anti-inflammatory and neuroprotective properties. A2A receptor activation is anti-inflammatory and may contribute to CBD's effects in inflammatory conditions. Caffeine works by blocking adenosine receptors — the opposite mechanism to CBD's adenosine-enhancing effects.
Related Terms
More in Pharmacology
Endocannabinoid System (ECS)
A lipid-based retrograde neurotransmitter system comprising endogenous cannabinoids (endocannabinoids), their receptors (CB1, CB2), and metabolic enzymes.
CB1 Receptor
Cannabinoid receptor type 1. A G protein-coupled receptor (GPCR) primarily expressed in the central nervous system. The primary target of THC's psychoactive effects.
CB2 Receptor
Cannabinoid receptor type 2. A GPCR primarily expressed in immune tissues and peripheral organs. Less abundant in the CNS than CB1.
Anandamide (AEA)
N-arachidonoylethanolamine. The first endocannabinoid identified. A partial agonist at CB1 and CB2 receptors, named from the Sanskrit word "ananda" meaning bliss.
2-Arachidonoylglycerol (2-AG)
The most abundant endocannabinoid in the brain. A full agonist at both CB1 and CB2 receptors.